These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

621 related items for PubMed ID: 25030731

  • 1. [Outcomes and prognostic factors of advanced squamous cervical cancer after concurrent chemoradiotherapy].
    Binbin T, Lingying W, Manni H, Jusheng A, Ning L.
    Zhonghua Fu Chan Ke Za Zhi; 2014 May; 49(5):348-54. PubMed ID: 25030731
    [Abstract] [Full Text] [Related]

  • 2. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC, Wang L, Lin JC, Jan JS.
    J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
    [Abstract] [Full Text] [Related]

  • 3. Outcomes and prognostic factors of cervical cancer after concurrent chemoradiation.
    Kim TE, Park BJ, Kwack HS, Kwon JY, Kim JH, Yoon SC.
    J Obstet Gynaecol Res; 2012 Nov; 38(11):1315-20. PubMed ID: 22612778
    [Abstract] [Full Text] [Related]

  • 4. [Outcomes and prognostic factors of distant metastasis in patients with advanced cervical squamous cell carcinoma treated with concurrent chemoradiotherapy].
    Ma R, Zhang H, Zou L, Qu Y.
    Zhonghua Fu Chan Ke Za Zhi; 2015 Feb; 50(2):125-30. PubMed ID: 25877610
    [Abstract] [Full Text] [Related]

  • 5. [Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors].
    Tang Q, Tu YQ, Chen JH, Lyu XJ, Yan DD.
    Zhonghua Zhong Liu Za Zhi; 2018 Jun 23; 40(6):462-466. PubMed ID: 29936774
    [Abstract] [Full Text] [Related]

  • 6. The Prognosis and Risk Stratification Based on Pelvic Lymph Node Characteristics in Patients With Locally Advanced Cervical Squamous Cell Carcinoma Treated With Concurrent Chemoradiotherapy.
    Li X, Wei LC, Zhang Y, Zhao LN, Li WW, Ping LJ, Dang YZ, Hu J, Shi M.
    Int J Gynecol Cancer; 2016 Oct 23; 26(8):1472-9. PubMed ID: 27400321
    [Abstract] [Full Text] [Related]

  • 7. Para-aortic and pelvic lymphadenectomy in locally advanced cervical cancer with pelvic lymph node metastasis.
    Jiang W, Zhong ML, Wang SL, Chen Y, Wang YN, Zeng SY, Liang MR.
    World J Surg Oncol; 2024 Sep 30; 22(1):262. PubMed ID: 39350212
    [Abstract] [Full Text] [Related]

  • 8. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
    Wang W, Hou X, Yan J, Shen J, Lian X, Sun S, Liu Z, Meng Q, Wang D, Zhao M, Qiu J, Hu K, Zhang F.
    BMC Cancer; 2017 Aug 01; 17(1):510. PubMed ID: 28764676
    [Abstract] [Full Text] [Related]

  • 9. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
    Mabuchi S, Isohashi F, Okazawa M, Kitada F, Maruoka S, Ogawa K, Kimura T.
    J Gynecol Oncol; 2017 Jan 01; 28(1):e15. PubMed ID: 27958682
    [Abstract] [Full Text] [Related]

  • 10. Low-dose, prophylactic, extended-field, intensity-modulated radiotherapy plus concurrent weekly cisplatin for patients with stage IB2-IIIB cervical cancer, positive pelvic lymph nodes, and negative para-aortic lymph nodes.
    Liang JA, Chen SW, Hung YC, Yeh LS, Chang WC, Lin WC, Chang YY.
    Int J Gynecol Cancer; 2014 Jun 01; 24(5):901-7. PubMed ID: 23975081
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
    Fujiwara M, Isohashi F, Mabuchi S, Yoshioka Y, Seo Y, Suzuki O, Sumida I, Hayashi K, Kimura T, Ogawa K.
    J Radiat Res; 2015 Mar 01; 56(2):305-14. PubMed ID: 25428244
    [Abstract] [Full Text] [Related]

  • 12. Comparison of salvage therapies for isolated para-aortic lymph node recurrence in patients with uterine cervical cancer after definitive treatment.
    Kubota H, Tsujino K, Sulaiman NS, Sekii S, Matsumoto Y, Ota Y, Soejima T, Yamaguchi S, Sasaki R.
    Radiat Oncol; 2019 Dec 26; 14(1):236. PubMed ID: 31878944
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of the survival outcome of neoadjuvant therapy followed by radical surgery with that of concomitant chemoradiotherapy in patients with stage IB2-IIIB cervical adenocarcinoma.
    Tian T, Gao X, Ju Y, Ding X, Ai Y.
    Arch Gynecol Obstet; 2021 Mar 26; 303(3):793-801. PubMed ID: 33009996
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Outcomes of chemoradiotherapy in cervical cancer--the Western Australian experience.
    Lim A, Sia S.
    Int J Radiat Oncol Biol Phys; 2012 Mar 15; 82(4):1431-8. PubMed ID: 21640504
    [Abstract] [Full Text] [Related]

  • 18. Adjuvant therapy after radical surgery for stage IB-IIB cervical adenocarcinoma with risk factors.
    Seki T, Tanabe H, Nagata C, Suzuki J, Suzuki K, Takano H, Isonishi S, Ochiai K, Takakura S, Okamoto A.
    Jpn J Clin Oncol; 2017 Jan 15; 47(1):32-38. PubMed ID: 27677664
    [Abstract] [Full Text] [Related]

  • 19. Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix.
    Huang EY, Huang YJ, Chanchien CC, Lin H, Wang CJ, Sun LM, Tseng CW, Tsai CC, Ou YC, Fu HC, Chen HC, Hsu HC, Wang CY.
    Radiat Oncol; 2012 Jan 30; 7():13. PubMed ID: 22289572
    [Abstract] [Full Text] [Related]

  • 20. Outcomes and toxicities for the treatment of stage IVB cervical cancer.
    Hwang JH, Lim MC, Seo SS, Kang S, Park SY, Kim JY.
    Arch Gynecol Obstet; 2012 Jun 30; 285(6):1685-93. PubMed ID: 22173823
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.